Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to -$2.0 million.

  • Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders rose 7109.98% to -$2.0 million in Q2 2025 from the same period last year, while for May 2025 it was -$44.4 million, marking a year-over-year decrease of 28015.27%. This contributed to the annual value of -$44.4 million for FY2025, which is 46925.83% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders is -$2.0 million, which was up 7109.98% from -$17.4 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Net Income towards Common Stockholders high stood at $15.6 million for Q1 2024, and its period low was -$51.6 million during Q2 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median Net Income towards Common Stockholders value was -$4.7 million (recorded in 2021), while the average stood at -$9.3 million.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders tumbled by 237678.66% in 2022 and then skyrocketed by 49439.67% in 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders (Quarter) stood at -$46.0 million in 2021, then skyrocketed by 92.17% to -$3.6 million in 2022, then soared by 494.4% to $14.2 million in 2023, then crashed by 161.21% to -$8.7 million in 2024, then soared by 76.48% to -$2.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$2.0 million in Q2 2025, compared to -$17.4 million in Q1 2025 and -$8.7 million in Q4 2024.